{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-264493","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2021-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.046276+00:00","generated_at":"2026-06-29T06:05:35.248252+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Forte Biosciences FB-401 Phase 2 atopic dermatitis trial misses primary endpoint EASI-50","bullets":["Primary endpoint EASI-50: 58% active vs 60% placebo (p=0.7567), not statistically significant.","Secondary endpoint EASI-90: 27.6% active vs 20.5% placebo (p=0.3075); IGA success: 38.2% vs 29.5% (p=0.2599).","Company will not continue development of FB-401; plans to provide future update on company direction.","Cash and cash equivalents of $50.8 million as of June 30, 2021.","Previously scheduled September 7 conference call canceled."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-264493","json":"https://secwatch.observer/filing/0001193125-21-264493.json","markdown":"https://secwatch.observer/filing/0001193125-21-264493.md","text":"https://secwatch.observer/filing/0001193125-21-264493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312521264493/0001193125-21-264493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312521264493/d88078d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T06:05:35.248252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}